Would a HIV vaccine be ready before the end of 2016?
The new clinical trial will examine a vaccine regimen specifically designed for virus subtype C
A pivotal clinical trial of a novel HIV vaccine regimen is expected to get underway in South Africa during 2016, according to AP.
Some 252 HIV-free South Africans to get the HVTN 100experimental regimen, which has been adapted to the HIV subtype that predominates in southern Africa. The regimen includes two separate vaccines, plus booster shots after one year. Pre-clinical trials suggest that it may confer at least 50% protection against the acquisition of HIV.
The safety and immunogenicity findings generated from the HVTN 100 trial will help determine whether this vaccine regimen will be tested in a larger study in South Africa.
According to ‘Contagion’ the Infectious Diseases Today’s magazine, the new clinical trial will examine a vaccine regimen specifically designed for virus subtype C, which is currently circulating the southern countries of Africa. This trial will build on the findings of the RV144 trial, led by a United States military program in Thailand, which found the vaccine to be 31.2% effective for 3.5 years after initial vaccination.
Two vaccines will be used together in the regimen to be examined in the HVTN 100 trial: ALVAC-HIV, a canarypox-based vaccine produced by Sanofi Pasteur; and a protein vaccine using an adjuvant to boost immune response, produced by Novartis Vaccines. According to the press release, the Phase I/II trial will enroll 252 HIV-uninfected heterosexual adults between the ages of 18 and 40 years, who will receive eight vaccine injections over one year, after which they will receive booster shots.
End of AIDS in sight? 10 facts about HIV/AIDS ahead of World AIDS DayDespite major advances, HIV/AIDS remains one of the world’s most significant public health challenges Variety
Almost 16 million on HIV treatment as AIDS pandemic tide turns15.8 million people are now on HIV treatment and a five-year strategy to end the threat of the AIDS pandemic as the U.N. AIDS program stated Variety
Don’t delay: Study confirms early treatment is best for HIVPeople who started anti-AIDS drugs while their immune system was strong were far less likely to develop AIDS Healthy Living
HIV-laced pages in magazine combat stigmaThe means through which the ink was developed ensure that handling the magazine would carry no risk of infection and is ‘100 percent safe’ Print